Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
Hand-out
Press Releases
January 9, 2025

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study

bradford

The Bradford Era

Local & Social